AIM
TBPH icon

Acrospire Investment Management’s Theravance Biopharma TBPH Stock Holding History

Acrospire Investment Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,690
Closed -$54K – 2480
2016
Q4 		$54K Buy
+1,690
New +$52.4K 0.02% 1354

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Acrospire Investment Management's TBPH Position: Q1 2017 in Review

Acrospire Investment Management sold out of Theravance Biopharma (TBPH) in Q1 2017, closing a stake of 1,690 shares — an estimated $54K sold.

Acrospire Investment Management first reported a position in TBPH in Q4 2016 and held it in 1 quarter. The position peaked at $54K in Q4 2016. 92 funds tracked by Wall St. Rank hold TBPH as of Q1 2017.

  • Acrospire Investment Management reported no remaining Theravance Biopharma position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 1,690 Theravance Biopharma shares in Q1 2017, an estimated $54K.
  • Acrospire Investment Management first reported a position in Theravance Biopharma in Q4 2016 and held it in 1 quarter.
  • Acrospire Investment Management's Theravance Biopharma position peaked at $54K in Q4 2016.
  • 92 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.